Skip to content
Open access

APOE ε4 Carrier Status and Cognitive Decline in Mild-to-Moderate Alzheimer's Disease: A Linear Mixed-Effects Analysis of the Placebo Arm of EXPEDITION 1

Sep 2026 · medRxiv · 0 citations
Medicine

Abstract

Background: Studies indicate that the apolipoprotein E (APOE) {varepsilon}4 allele is the strongest genetic risk factor for Alzheimer's disease (AD), and individuals with this allele are at increased risk of developing AD, there remains debate regarding whether APOE {varepsilon}4 carriers experience more rapid cognitive decline over time compared to non-carriers. This study assessed this question using linear mixed-effects models applied to the placebo arm of EXPEDITION 1, a phase 3 clinical trial evaluating solanezumab in patients with mild-to-moderate Alzheimers disease. Methods: In this study we utilized data from 370 participants in the placebo group of the EXPEDITION 1 trial. After excluding 27 participants with undefined APOE genotype, all models and analyses were applied to the remaining 343 participants (686 ADAS-Cog14 observations) to determine whether APOE {varepsilon}4 carriers exhibit a faster rate of decline over the 80-week follow-up period. Five nested linear mixed-effects models with a participant-specific random intercept were fitted, and also a complementary change-score analysis was done. Results: Over 80 weeks, ADAS-Cog14 worsened by an average of 7.01 points. Carriers did not decline faster than non-carriers (additional decline 1.31 points; 95% CI -1.22 to 3.83; p = 0.310), and the change-score analysis showed the same pattern. Carriers had worse ADAS-Cog14 scores overall, but this difference was no longer significant after adjustment for baseline CDR-SB. Conclusion: In this cohort, APOE {varepsilon}4 carrier status was related to disease severity at baseline rather than to the rate of cognitive decline over 80 weeks.

Read PDF

Similar papers

Nov 2026

Role of APOE ɛ4 and ɛ2 With Longitudinal Cognitive Decline Among Those With Exceptional Longevity: The LifeAfter90 Study.

BACKGROUND AND OBJECTIVES APOE ɛ4 is the strongest genetic risk factor for late-onset Alzheimer disease, while ɛ2 is associated with decreased risk. However, it is unclear how these genotypes relate to cognitive decline among those aged older than 90+. We examined associations of ɛ4 and ɛ2 with longitudinal change in 3...

H. Colbeth, A. Posis, Batool Rizvi et al. · 0 citations
Open access Oct 2026

Association of APOE Ε4 Genotype With Lipid Profile in Patients With Alzheimer's Disease

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which genetic susceptibility and disturbances in lipid metabolism contribute to disease onset and progression. The Apolipoprotein E (APOE) ε4 allele has been consistently implicated in late-onset AD, while alterations in circulating lip...

S. S, Senthil Kumar, Shankar et al. · 0 citations
Oct 2026

B-325 APOE Genetic Testing and E4 Allele Frequency in a Clinical Population: Implications for Alzheimer’s Disease Risk Stratification

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder worldwide and represents a major public health challenge driven by population aging. It is estimated that more than 50 million people currently live with dementia, with AD accounting for 60–70% of cases, and projections exceeding 150 millio...

F. Mattesco, M. Souza, Jorge Borges et al. · 0 citations
Open access Sep 2026

APOE-stratified genome-wide association analyses provide insights into the genetic etiology of Alzheimers’s disease

Understanding of the genetic architecture of AD in the context of its main genetic driver is improved, and APOE-stratified insights may help understand and overcome side effects, inform clinical trial enrollment strategies, and create the scientific basis for targeted, mechanism-driven therapies in neurodegenerative di...

J. Thomassen, H. Leonard, Brittany Ulms et al. · 0 citations
Open access Oct 2026

A-105: Early Cognitive and Behavioral Outcomes in Child Carriers and Non-Carriers: Preliminary Findings From the Longitudinal NeuroKids Autosomal Dominant Alzheimer’s Disease Study

Objective: Individuals carrying the Presenilin-1 (PSEN1) E280A mutation are nearly certain to develop autosomal dominant Alzheimer’s disease (ADAD) by their forties. Although presymptomatic differences have been observed in adults decades before symptom onset, the earliest divergence remains unknown. This ongoing lon...

Meredith C. Rowe, N. Londoño, Sarita Firstman Lamus et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.